Synapse - Gunjan Shah

Results (244)

Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality

Journal Article

Stahl, M.; Narendra, V.; Jee, J.; Derkach, A.; Maloy, M.; Geyer, M. B.; Mato, A. R.; Roeker, L. E.; Tallman, M. S.; Shah, G. L.; more...
Leukemia and Lymphoma (2021)

Fulltext@MSK | Save

Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial

Journal Article

Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
JAMA Oncology (2021)

Fulltext@MSK | Save

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Journal Article

Dahi, P. B.; Lee, J.; Devlin, S. M.; Ruiz, J.; Maloy, M.; Rondon-Clavo, C.; Petrlik, E.; Tamari, R.; Shah, G.; Scordo, M.; more...
Blood Advances (2021)

Fulltext@MSK | Save

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial

Journal Article

Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone

Research Letter

Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
American Journal of Hematology (2021)

Fulltext@MSK | Save

The International Prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy

Journal Article

Garcia-Recio, M.; Wudhikarn, K.; Pennisi, M.; Alonso-Trillo, R.; Flynn, J.; Shouval, R.; Afuye, A. O.; Silverberg, M. L.; Batlevi, C. W.; Dahi, P.; more...
Transplantation and Cellular Therapy (2021)

Fulltext@MSK | Save

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: A multicenter observational study

Journal Article

Khan, N.; Lindner, S.; Gomes, A. L. C.; Devlin, S. M.; Shah, G. L.; Sung, A. D.; Sauter, C. S.; Landau, H. J.; Dahi, P. B.; Perales, M. A.; more...
Blood (2021)

Fulltext@MSK | Save

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

Research Letter

Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, H. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
Haematologica (2021)

Fulltext@MSK | Save

VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup